MX2018009944A - Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. - Google Patents
Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.Info
- Publication number
- MX2018009944A MX2018009944A MX2018009944A MX2018009944A MX2018009944A MX 2018009944 A MX2018009944 A MX 2018009944A MX 2018009944 A MX2018009944 A MX 2018009944A MX 2018009944 A MX2018009944 A MX 2018009944A MX 2018009944 A MX2018009944 A MX 2018009944A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- dihydropirimidin
- alcoxicarbon
- carboxilico
- pirazin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención, se refiere a un procedimiento para la sintetización de un compuesto de la fórmula (I), (ver fórmula) (I), R1 es fenilo, el cual se encuentra sustituido o insustituido con uno, dos o tres sustituyentes, independientemente seleccionados de entre halógeno y alquilo C1-6; R2, es alquilo C1-6; R3, es -CxH2x-; x, es 1, 2, 3, 4, 5, 6 ó 7; ó una sal o un diastereómero de éste, farmacéuticamente aceptable, el cual es de utilidad, para la profilaxis y el tratamiento de una enfermedad vírica, en un paciente, relativa a una infección por hepatitis B, o a una enfermedad causada por la infección por hepatitis B.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016074132 | 2016-02-19 | ||
| PCT/EP2017/053443 WO2017140750A1 (en) | 2016-02-19 | 2017-02-16 | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018009944A true MX2018009944A (es) | 2018-11-09 |
| MX380516B MX380516B (es) | 2025-03-12 |
Family
ID=58054130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009944A MX380516B (es) | 2016-02-19 | 2017-02-16 | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10927116B2 (es) |
| EP (2) | EP3954691A1 (es) |
| JP (1) | JP6672471B2 (es) |
| KR (2) | KR20210059801A (es) |
| CN (1) | CN108718527B (es) |
| AR (1) | AR107633A1 (es) |
| AU (2) | AU2017219189B2 (es) |
| ES (1) | ES2899369T3 (es) |
| HR (1) | HRP20211816T1 (es) |
| IL (2) | IL260153B (es) |
| MX (1) | MX380516B (es) |
| PL (1) | PL3416966T3 (es) |
| SG (2) | SG11201805595TA (es) |
| SI (1) | SI3416966T1 (es) |
| WO (1) | WO2017140750A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3114128T (pt) * | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b. |
| US11142527B2 (en) | 2017-06-26 | 2021-10-12 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| EP3645516A4 (en) | 2017-06-27 | 2021-07-07 | Janssen Pharmaceutica NV | HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS |
| EP3697792A4 (en) * | 2017-10-18 | 2021-10-13 | Sunshine Lake Pharma Co., Ltd. | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN MEDICINE |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| TW202035412A (zh) * | 2018-12-20 | 2020-10-01 | 比利時商健生藥品公司 | 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法 |
| US20220048919A1 (en) * | 2018-12-20 | 2022-02-17 | Janssen Phrmaceutica NV | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
| WO2020193459A1 (en) | 2019-03-25 | 2020-10-01 | F. Hoffmann-La Roche Ag | Solid forms of a compound of hbv core protein allosteric modifier |
| KR20220018486A (ko) * | 2019-06-06 | 2022-02-15 | 에프. 호프만-라 로슈 아게 | 4-페닐-5-알콕시카르보닐-2-티아졸-2-일-1,4-디히드로피리미딘-6-일]메틸]-3-옥소-5,6,8,8a-테트라히드로-1H-이미다조[1,5-a]피라진-2-일]-카르복실산을 제조하는 대체 방법 |
| US20220241402A1 (en) | 2019-06-18 | 2022-08-04 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
| MX2022001261A (es) * | 2019-07-31 | 2022-05-03 | Janssen Sciences Ireland Unlimited Co | Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. |
| CN112707910A (zh) * | 2019-10-24 | 2021-04-27 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| BR112022021928A2 (pt) * | 2020-04-28 | 2022-12-13 | Hoffmann La Roche | Processo para a preparação de um ácido piperazina-2-carboxílico quiral |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10125131A1 (de) | 2001-05-23 | 2002-12-05 | Bayer Ag | Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats |
| CN100453542C (zh) | 2007-04-30 | 2009-01-21 | 广东东阳光药业有限公司 | 2-杂环取代的二氢嘧啶消旋化合物的拆分方法 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| PL2888241T3 (pl) | 2012-08-24 | 2017-12-29 | Sunshine Lake Pharma Co., Ltd. | 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby |
| BR112015004113A2 (pt) | 2012-09-10 | 2017-07-04 | Hoffmann La Roche | 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
| US9266904B2 (en) | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| PT3114128T (pt) * | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b. |
| AR101319A1 (es) * | 2014-07-31 | 2016-12-07 | Hoffmann La Roche | Resolución quiral de los ésteres del ácido 4-aril-2-tiazol-2-il-1,4-dihidropirimidin-5-carboxílico |
| AR103222A1 (es) | 2014-12-23 | 2017-04-26 | Hoffmann La Roche | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina |
-
2017
- 2017-02-15 AR ARP170100377A patent/AR107633A1/es active IP Right Grant
- 2017-02-16 JP JP2018543245A patent/JP6672471B2/ja active Active
- 2017-02-16 HR HRP20211816TT patent/HRP20211816T1/hr unknown
- 2017-02-16 KR KR1020217014633A patent/KR20210059801A/ko not_active Ceased
- 2017-02-16 KR KR1020187026098A patent/KR102255228B1/ko active Active
- 2017-02-16 MX MX2018009944A patent/MX380516B/es unknown
- 2017-02-16 EP EP21193914.5A patent/EP3954691A1/en not_active Withdrawn
- 2017-02-16 AU AU2017219189A patent/AU2017219189B2/en active Active
- 2017-02-16 EP EP17705612.4A patent/EP3416966B1/en active Active
- 2017-02-16 SG SG11201805595TA patent/SG11201805595TA/en unknown
- 2017-02-16 SI SI201730991T patent/SI3416966T1/sl unknown
- 2017-02-16 PL PL17705612T patent/PL3416966T3/pl unknown
- 2017-02-16 SG SG10202110927VA patent/SG10202110927VA/en unknown
- 2017-02-16 CN CN201780011960.XA patent/CN108718527B/zh active Active
- 2017-02-16 WO PCT/EP2017/053443 patent/WO2017140750A1/en not_active Ceased
- 2017-02-16 ES ES17705612T patent/ES2899369T3/es active Active
-
2018
- 2018-06-19 IL IL260153A patent/IL260153B/en unknown
- 2018-08-20 US US15/999,701 patent/US10927116B2/en active Active
-
2021
- 2021-06-10 AU AU2021203860A patent/AU2021203860A1/en not_active Abandoned
- 2021-10-03 IL IL286912A patent/IL286912A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3416966T1 (sl) | 2022-01-31 |
| MX380516B (es) | 2025-03-12 |
| AR107633A1 (es) | 2018-05-16 |
| CN108718527A (zh) | 2018-10-30 |
| EP3416966B1 (en) | 2021-09-29 |
| KR20180104177A (ko) | 2018-09-19 |
| ES2899369T3 (es) | 2022-03-11 |
| IL286912A (en) | 2021-10-31 |
| AU2017219189A1 (en) | 2018-06-28 |
| JP6672471B2 (ja) | 2020-03-25 |
| EP3954691A1 (en) | 2022-02-16 |
| AU2017219189B2 (en) | 2021-04-01 |
| JP2019507144A (ja) | 2019-03-14 |
| US10927116B2 (en) | 2021-02-23 |
| SG10202110927VA (en) | 2021-11-29 |
| WO2017140750A1 (en) | 2017-08-24 |
| IL260153A (en) | 2018-07-31 |
| EP3416966A1 (en) | 2018-12-26 |
| SG11201805595TA (en) | 2018-07-30 |
| CN108718527B (zh) | 2022-06-28 |
| US20190010155A1 (en) | 2019-01-10 |
| CA3011650A1 (en) | 2017-08-24 |
| IL260153B (en) | 2021-10-31 |
| BR112018016932A2 (pt) | 2019-01-08 |
| PL3416966T3 (pl) | 2022-01-17 |
| KR102255228B1 (ko) | 2021-05-25 |
| HRP20211816T1 (hr) | 2022-03-04 |
| AU2021203860A1 (en) | 2021-07-08 |
| KR20210059801A (ko) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
| AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
| PH12017501258B1 (en) | Pyrazine compounds for the treatment of infectious diseases | |
| ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| UY35263A (es) | Compuestos terapéuticos | |
| NZ739248A (en) | Inhibitors of hepatitis c virus | |
| MX2018010805A (es) | Agentes antivirales contra la hepatitis b. | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| PH12019500432A1 (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| AR094966A1 (es) | Composiciones farmacéuticas para el tratamiento de infecciones hcv | |
| AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
| DOP2014000121A (es) | Derivados de betulina | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты | |
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| EA201991349A1 (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с | |
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b |